Reading Time: 7 minutesIn November 2018 the Home Office released a draft Guideline scope for Cannabis-based products for medicinal use in which they announced that specialist doctors (like
Category: Treatments
Reading Time: 5 minutesThere has recently been a flood of news stories on the outcomes of the Australian Phase 1 clinical trial investigating Copper ATSM (CuATSM) which is
Reading Time: 3 minutesThis blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 2 minutesThe research team frequently gets asked about the effectiveness of alternative therapies and their use as treatments for MND. Here we report on a recent
Reading Time: 7 minutesIn the last decade, the MND Association has invested millions in research within the UK and across the world. We are a leader in the
Reading Time: 2 minutesIn their official press release published on 21 November 2017, Cytokinetics Inc. announced that they will not be continuing work on tirasemtiv after disappointing results
Reading Time: 3 minutesAt last year’s Airlie House workshop to develop new ALS/MND Clinical Trial Guidelines the focus was, of course, on MND, but there was also important input
Causes and disease mechanisms Clinical Trials Markers of Disease Progression MND Research Research we fund
Lighthouse Project shines a beacon on HERVs and their role in ALS
Reading Time: 3 minutesThere is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to
Reading Time: 5 minutesIt’s been over a month since the announcement by the FDA of their decision to licence edaravone / Radicava for people with MND in the
Reading Time: 4 minutesEach year, the MND Association dedicates the month of June to raising MND awareness. This year, we focus on the eyes – in most people